Brazil's SUS Struggles to Incorporate Weight-Loss Injections Amidst Rising Obesity Rates
Brazil's Unified Health System (SUS) currently does not offer any weight-loss injection treatments for obesity, and there are no immediate plans for their inclusion in the public healthcare network. This situation persists despite obesity rates soaring in the country, with 25.7% of Brazilian adults affected in 2024, a significant increase from 11.8% in 2006. The SUS primarily relies on bariatric surgery, which has long waiting lists, and offers no other medications for obesity treatment. While the Ministry of Health acknowledges the importance of these advanced medications, their high cost has been a major barrier. Previously, requests to incorporate liraglutide and semaglutide were denied due to an estimated budgetary impact exceeding R$8 billion. However, the expiration of semaglutide's patent in March 2024 has opened doors for domestic production at lower costs, prompting the Ministry of Health to expedite the registration of GLP-1 agonist medications. Several Brazilian pharmaceutical companies have since submitted and received approvals for semaglutide-based drugs, with the first domestic version, Ozivy, already available. The Ministry anticipates that increased competition and generic availability will significantly reduce prices, making incorporation into SUS more feasible. A pilot project in Porto Alegre is currently evaluating the real-world application and costs of semaglutide treatment for 250 patients awaiting bariatric surgery. Experts believe the country is closer than ever to incorporating these medications, especially with the drastic price drop of semaglutide following patent expiry. Novo Nordisk has also resubmitted a proposal for semaglutide inclusion with a significant discount and specific patient criteria, focusing on high-risk individuals. While initial access is expected to be restricted, experts see this as a crucial step towards better obesity management within SUS, potentially leading to reduced healthcare costs and improved quality of life. They also emphasize that medication must be part of a comprehensive approach including nutritional guidance and physical activity.
The Brazilian public health system's challenge in adopting novel obesity treatments like GLP-1 agonists highlights a recurring tension between medical innovation and fiscal sustainability. The high cost of these advanced therapies, even post-patent expiry, necessitates careful resource allocation within a system serving a vast population. The recent pilot program and the emergence of domestic generic options suggest a strategic shift towards balancing access with affordability. However, the long-term viability of incorporating such treatments hinges on continued price reductions, robust efficacy data within the public health context, and a comprehensive approach that integrates medication with lifestyle interventions. The system's capacity to manage chronic diseases like obesity effectively will be a key indicator of its adaptability to the evolving landscape of pharmaceutical advancements and public health demands over the next decade.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.
